Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. The capital will finance the preclinical work and the development of a production method up to the start of toxicology studies next year.

See the full interview (in swedish) from BioStock with our CEO Einar Pontén where he also talks about the plans for a market listing in 2020 and the interest from venture capital companies.